Skip to main content

Johns Hopkins

Johns Hopkins Pediatric

Next-Generation Therapy for Early Bladder Cancer: Nanoparticles

January 01, 2017

It’s a very high-tech, miniaturized version of the “quicker picker-upper.”

About 75 percent of people who have bladder cancer are diagnosed when it is in the early stage; this is non-muscle invasive bladder cancer (NMIBC). 

In clinical trials, chemotherapy drugs such as docetaxel and cisplatin are being tested on NMIBC that is unresponsive to BCG. However, when these drugs are placed in the bladder, they don’t easily penetrate into the tissue to reach cancerous cells, they’re rapidly cleared from the bladder, and they can enter the bloodstream, potentially causing systemic side effects.

Maybe they need repackaging. Urologist Max Kates, M.D., with colleagues Abhijit Date, Ph.D., and Laura Ensign-Hodges, Ph.D., have taken a novel approach, combining nanoparticles with “absorption-enhancing vehicles” that make sure most of the medicine gets absorbed by the bladder tissue, and less goes into the bloodstream. It’s a very high-tech, miniaturized version of the “quicker picker-upper.” Based on successful lab tests of these novel nanoparticle combinations, Phase 1 clinical trials are in the works. These findings were published in European Urology.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.